| __timestamp | Amneal Pharmaceuticals, Inc. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 84615000 | 35942000 |
| Thursday, January 1, 2015 | 109679000 | 40028000 |
| Friday, January 1, 2016 | 118757000 | 45853000 |
| Sunday, January 1, 2017 | 109046000 | 53816000 |
| Monday, January 1, 2018 | 230435000 | 60804000 |
| Tuesday, January 1, 2019 | 289598000 | 77252000 |
| Wednesday, January 1, 2020 | 326727000 | 45736000 |
| Friday, January 1, 2021 | 365504000 | 50323000 |
| Saturday, January 1, 2022 | 399700000 | 143526000 |
| Sunday, January 1, 2023 | 429675000 | 149182000 |
| Monday, January 1, 2024 | 154335000 |
In pursuit of knowledge
In the competitive pharmaceutical landscape, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Amneal Pharmaceuticals, Inc. and Halozyme Therapeutics, Inc. have demonstrated contrasting approaches to SG&A cost management. From 2014 to 2023, Amneal's SG&A expenses surged by over 400%, peaking at approximately $430 million in 2023. In contrast, Halozyme's expenses grew by around 315%, reaching nearly $149 million in the same year.
While Amneal's expenses consistently outpaced Halozyme's, the latter maintained a more stable growth trajectory, suggesting a more controlled cost management strategy. This difference highlights the importance of strategic financial planning in the pharmaceutical industry, where efficient SG&A management can significantly impact a company's bottom line. As investors and stakeholders evaluate these companies, understanding their cost management strategies becomes essential for making informed decisions.
Breaking Down SG&A Expenses: Sanofi vs Amneal Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Viatris Inc. and Halozyme Therapeutics, Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs Amneal Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Amneal Pharmaceuticals, Inc.
Halozyme Therapeutics, Inc. and Apellis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Halozyme Therapeutics, Inc. or ADMA Biologics, Inc.: Who Manages SG&A Costs Better?
Halozyme Therapeutics, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs Bausch Health Companies Inc.
Breaking Down SG&A Expenses: Amneal Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Soleno Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Amneal Pharmaceuticals, Inc. and MiMedx Group, Inc.